Company / R&D Expense
Coherus Oncology, Inc. R&D Expense History
FY2014-FY2019 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$94.2M
FY2019
5-year range
$31.3M / $162.4M
FY2015-FY2019
Trend
-14.6%
vs FY2018
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $162M to $94M over the past 2 years.
Based on SEC 10-K filings.
$94M in FY2019 with a 5-year CAGR of +22.0%.
Declined from $162M to $94M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +6.4%
- 5-Year CAGR
- +22.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +22.0%, indicating consistent growth.
- In FY2019, r&d expense decreased 14.6% year-over-year.
- Peak r&d expense was recorded in FY2017.
- Lowest r&d expense in the period was in FY2015.
Company context
Key Data Points
- Altman Z-Score -0.49 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2019 | $94.2M | -14.6% |
| FY2018 | $110.2M | -32.1% |
| FY2017 | $162.4M | +107.6% |
| FY2016 | $78.2M | +150.1% |
| FY2015 | $31.3M | -10.3% |
| FY2014 | $34.9M | - |
As of FY2019 · SEC 10-K · Updated Jun 24, 2026